T he advent of intravitreous anti-vascular endothelial growth factor (VEGF) injections to treat common causes of vision loss, such as exudative age-related macular degeneration (AMD), [1] [2] [3] diabetic macular edema, 4-6 and edema associated with retinal vein occlusion, 7-10 has undoubtedly improved visual outcomes for many patients. Major prospective clinical trials investigating variable dosing regimens of intravitreous anti-VEGF injections for exudative AMD have revealed that some patients may require monthly injections during the first 1 to 2 years of treatment and that, on average, 10 injections are required in the first 2 years of treatment.
11,12
Minimal adverse events were reported in those trials and some conflicting results exist, but subsequent studies suggest that repeated intravitreous anti-VEGF injections can lead to a sustained increase in intraocular pressure (IOP).
13-22
In 2007, Jalil and colleagues 13 reported a case of ocular hypertension with a marked rise in IOP 3 days after the patient's fourth monthly intravitreous injection of bevacizumab for exudative AMD. In 2008, Bakri and colleagues 14 reported a case series of 4 nonglaucomatous patients receiving intravitreous ranibizumab who developed a sustained increase in IOP. Similar studies have been published since those initial case series, including research suggesting that intravitreous bevacizumab injections cause sustained increases in IOP. 15, 16 Retrospective chart reviews support this association, reporting that approximately 6% to 9% of patients receiving intravitreous anti-VEGF injections experienced sustained IOP elevation.
17-19
A similar value was observed in an exploratory analysis of the Diabetic Retinopathy Clinical Research Network randomized clinical trial. 20 Many of those studies suggest that the risk of sustained IOP rise is positively associated with the number of injections that the patient has received. 16, 17, 21 To date, there has not been a large epidemiologic study that has investigated the risk of a clear glaucoma outcome (ie, less prone to bias using a retrospective health database analysis), such as glaucoma surgery, following repeated intravitreous anti-VEGF injections. Intravitreous injections of anti-VEGF agents may increase the risk of increased IOP [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] ; however, the risk of developing moderate to advanced glaucoma requiring glaucoma surgery has been unclear. A single, small case series suggests that at least some patients with or without glaucoma at baseline may go on to require a trabeculectomy. 22 Therefore, using large, population-based linked health databases, we conducted a pharmacoepidemiologic, nested, casecontrol study to examine the possible association of repeated intravitreous bevacizumab injections with subsequent glaucoma surgery.
Methods

Setting and Patient Population
This population-based, observational study used the linked databases supported by the British Columbia Ministry of Health. In British Columbia, Canada, patients with retinal diseases are entitled to receive anti-VEGF medication through the Provincial Retinal Diseases Treatment Program. The program records clinical ophthalmic data for all patients, including intravitreous anti-VEGF injections, in a comprehensive database that is subject to frequent quality control and is linkable to other Ministry of Health-supported databases. These databases have been used in many previous epidemiologic studies [23] [24] [25] 
Cohort and Case-Control Analysis
The cohort comprised patients who received their first intravitreous bevacizumab injection for exudative AMD between January 1, 2009, and December 31, 2013. Cases were defined as patients in the cohort who subsequently underwent glaucoma surgery. The date of glaucoma surgery was the index date. For each case, 10 controls (no surgical procedure code at any time of follow-up) were selected and matched by age, preexisting glaucoma, number of injections per year, calendar time, and follow-up time (matching protocol below). Glaucoma surgery cases were identified using these surgical procedural codes, which are part of the payment schedule created by the Medical Services Commission to reimburse services clinicians provide to beneficiaries of the Medical Services Plan: trabeculectomy (02187), complicated trabeculectomy (22187), glaucoma drainage device (22070), and cycloablative procedure (22185). Calendar time and follow-up time matching was achieved by selecting controls who received their first bevacizumab injection in the same year and had the same duration of follow-up as the cases between injection and date of glaucoma surgery (index date). Calendar time matching decreases the likelihood that trends for a particular procedure that differ by calendar year (eg, introduction of new guidelines for a specific procedure) will affect cases and controls disproportionately. Matching by follow-up time balances between cases
Key Points
Question Do repeated intravitreous bevacizumab injections increase the risk for glaucoma surgery?
Finding In this case-control study of 74 patients who underwent glaucoma surgery and 740 control participants, the adjusted rate ratio for glaucoma surgery was higher for patients who received 7 or more intravitreous bevacizumab injections per year than for those who received 3 or fewer intravitreous bevacizumab injections per year.
Meaning Patients who receive 7 or more intravitreous bevacizumab injections per year have an increased risk of requiring glaucoma surgery.
and controls the opportunity to undergo glaucoma surgery, controlling for time window bias. 25 Cases and controls were matched for preexisting glaucoma to control for the increased probability of glaucoma surgery in patients with preexisting glaucoma. The exposure investigated was the frequency of intravitreous bevacizumab injections in cases and controls. Thresholds of the number of injections received per year were 3 or fewer, 4 to 6, or 7 or more; these cutoffs were chosen to ensure a robust sample size in the reference category. Data were analyzed in the same manner but with the total number of intravitreous bevacizumab injections as the exposure and the thresholds as 6 or fewer, 7 to 11, or 12 or more (eTable in the Supplement).
Intravitreous Anti-VEGF Injections
Bevacizumab is the anti-VEGF medication provided by the Provincial Retinal Diseases Treatment Program to most patients in British Columbia with exudative AMD. In this study, bevacizumab was also the anti-VEGF medication used for all patients in the cohort. A licensed pharmacist at a compounding pharmacy, approved by the College of Pharmacists of British Columbia and the Provincial Retinal Diseases Treatment Program, compounds and dispenses bevacizumab. Commercially available vials of the anti-VEGF medication, which is supplied by the Ministry of Health, are used to fill ultrafine diabetic syringes (BD ultrafine II ½ CC syringes; BD Worldwide) containing 0.05 mL of the drug. The syringes are then transported and stored at 4°C until used by the vitreoretinal specialist.
Statistical Analysis
The demographics of cases and controls were examined using descriptive statistics. For the case-control analysis, patients who received 3 or fewer injections per year (or ≤6 total injections in the supplementary analysis) served as the reference category. Controls were allowed to become future cases (ie, experience a future surgical procedure), allowing the odds ratio to closely approximate a rate ratio (RR) derived from a cohort study. 30 Crude and adjusted RRs were approximated from a conditional logistic regression model. The RRs were adjusted for the following covariates: diabetes, myocardial infarction, stroke, and verteporfin use (Visudyne; Novartis and QLT PhotoTherapeutics). To avoid indiscriminant adjustment of covariates that may lead to overadjustment bias, causal diagrams of potential confounding variables were used to identify true confounding variables (ie, variables that appear to be associated with exposure and outcome) and adjustment of covariates at baseline.
31,32
Results
We identified the cases of 75 patients who had received intravitreous bevacizumab injections for exudative AMD. One patient also had a central retinal vein occlusion and was excluded from the study, leaving 74 cases for analysis. We identified 740 corresponding controls who were matched for age and preexisting glaucoma. The mean (SD) age was 81.3 (8.4) years for cases and was 81.4 (7.9) years for controls ( Table 1) . Table 2 ). Compared with the reference group (ie, those who received ≤3 intravitreous bevacizumab injections per year), an increased RR was observed for cases vs controls who received 7 or more intravitreous bevacizumab injections per year (adjusted RR, 2.48; 95% CI, 1.25-4.93). Compared with the reference group, there was no difference in the RR for cases vs controls who received 4 to 6 intravitreous bevacizumab injections per year (adjusted RR, 1.65; 95% CI, 0.84-3.23). These data show that receipt of 7 or more, but not 4 to 6, intravitreous bevacizumab injections per year is associated with an increased risk of subsequent glaucoma surgery. Similar results were obtained when the total number of injections were used as the exposure group (eTable in the Supplement).
Discussion
Several case reports, retrospective studies, and post hoc exploratory analyses of prospective clinical trials 13-22 have associated intravitreous injections of anti-VEGF agents with a sus- The present study was restricted to use of the VEGF inhibitor bevacizumab because this medication is supported by the Provincial Retinal Diseases Treatment Program and is widely used by most of its patients. Previous studies suggest that the putative effect of intravitreous anti-VEGF injections on IOP, and possibly on glaucoma, may not be produced by bevacizumab alone. Case studies have suggested that the effect of intravitreous anti-VEGF medications on sustained increased IOP is the result of both bevacizumab and ranibizumab. [13] [14] [15] [16] 19 In a retrospective review by Choi and colleagues, 18 sustained IOP elevation occurred after intravitreous injections of bevacizumab, ranibizumab, or pegaptanib sodium. In the case series by Skalicky and colleagues, 22 all patients who went on to require a trabeculectomy had received ranibizumab. Larger studies are required to clarify any potential differences in effects of repeated intravitreous injections of different anti-VEGF agents on the need for glaucoma surgery.
Strengths and Limitations
Our study has many important strengths. First, its large sample size allowed for appropriate quantification of the relationship between the frequency (and total number; see eTable in the Supplement) of repeated intravitreous bevacizumab injections and surgical intervention for glaucoma. The use of glaucoma surgery as a hard outcome is a novel approach to addressing the potential association between glaucoma and intravitreous bevacizumab injections; previous large studies were limited to associations between repeated intravitreous anti-VEGF injections and sustained increases in IOP. Second, the study design involved the matching of preexisting glaucoma between cases and controls to decrease the possibility of preexisting glaucoma confounding our results, such as an increased baseline likelihood for glaucoma surgery between groups. Third, restricting the study to only patients who received intravitreal bevacizumab injections for the indication of exudative AMD was important because central retinal vein occlusion, a separate condition associated with glaucoma, may also be treated by intravitreous bevacizumab injections. Finally, the study demonstrates that a greater frequency and a greater total number of bevacizumab injections (eTable in the Supplement) are both associated with an increased risk for glaucoma surgery; this supports the robustness of our results. One limitation of this study is that, although the databases we used are well linked and subject to rigorous quality control, they did not allow us to access details of individual disease severity and trajectory, including data such as changes in IOP and visual field loss. Similarly, making associations with prescription of glaucoma medications is difficult when prescribing practices are not reliably linked with bona fide glaucoma diagnoses. Second, this study was unable to address the issue of compounded vs prepared anti-VEGF medication because all anti-VEGF medication was compounded bevacizumab. Previous studies have shown the differences in protein concentration, aggregation, and particulate matter between compounded and prepared anti-VEGF medication. 37, 38 Finally, it is important to appreciate that, in general, causation cannot be conclusively established in case-control studies. 
